Navigation Links
New drug is effective against the most common form of skin cancer
Date:4/6/2011

ORLANDO, Fla. April 5, 2011 A new drug is effective in preventing new basal cell carcinomas in patients with an inherited predisposition to the disease.

These patients with basal cell nevus syndrome develop large numbers of basal cells, which can become locally invasive or metastatic, according to a discussion presented by renowned oncologist Dr. Daniel D. Von Hoff at the 102nd annual meeting of the American Association for Cancer Research (AACR).

In an initial study, Dr. Von Hoff and his team at TGen Clinical Research Service at Scottsdale Healthcare (TCRS) found that the drug, vismodegib (GDC-0449), a hedgehog pathway inhibitor, was effective in shrinking advanced invasive or metastatic basal cell carcinomas. TCRS was the first to evaluate vismodegib, produced by Genentech. TCRS is a partnership of the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Ariz.

At Sunday's conference plenary session, titled: "The Future of Cancer Research: Challenges and Opportunities," Dr. Von Hoff discussed a new prevention and treatment approach for patients who have basal cell nevus syndrome. Specifically, he discussed the effect of the drug on basal cell nevus syndrome, an advanced form of basal cell carcinoma that produces often-disfiguring tumors of the jaw, the sole of the foot, the brain and ribs.

A team of investigators from Children's Hospital Oakland Research Institute (CHORI) in Oakland, Calif., headed by Dr. Ervin H. Epstein Jr., presented dramatic results at the conference demonstrating that vismodegib entirely prevented the development of basal cell carcinomas in patients with basal cell nevus syndrome.

These findings are "a stunning result, which brings hope to patients who otherwise may need disfiguring surgery, especially for cancers that arise on the face and upper part of the body," said Dr. Von Hoff, a past president of AACR.

"We are so pleased that the results obtained by TCRS could be a part of the work that has made a difference for so many patients," said Dr. Von Hoff, who also is Physician-In-Chief and Distinguished Professor at TGen; Chief Scientific Officer at Scottsdale Healthcare and US Oncology; and Professor of Medicine at Mayo Clinic.

Basal cell nevus syndrome is an inherited genetic disease, which results in the development of multiple, sometimes hundreds of basal cell carcinomas. The sporadic (non-inherited) form of basal cell carcinoma is the most common skin cancer. While most cases are curable, in some patients there is a tendency for recurrent cancers and surgery may not be possible.

More than 15,000 physicians and researchers from across the globe attend the annual AACR conference, which runs April 2-6 at the Orange County Convention Center in Orlando, FL.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology technology :

1. QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery
2. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
3. Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study
4. bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing?
5. Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development
6. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
7. New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution
8. United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies
11. Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading ... today announced the completion of a significant transaction and partnership that positions Amendia ... and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm ...
(Date:4/29/2016)... , April 29, 2016 Elekta ... latest update to its industry-leading treatment planning software, is ... Monaco version 5.11 provides significant ... attain calculation speeds up to four times faster than ... With the industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... ... April 28, 2016 , ... As part of an ... experts, and expanding its LATAM network and logistics capabilities. Enhancements have been ... their clinical trial projects. , The expansion will provide unmatched clinical trial logistics ...
(Date:4/27/2016)... ... 27, 2016 , ... Most consumers engage with biometrics technology ... secure access, voice recognition for hands-free communication, and facial recognition to help organize ... technology today. But if they asked Joey Pritikin, Vice President of Marketing ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):